Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remote personalized treatment optimization with empagliflozin and finerenone in type 2 diabetes with albuminuria
NL-OMON59957Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin and finerenone in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis, sponsored by University Medical Center Groningen. Primary endpoints: Participant feasibility questionnaire, Urine sample collection feasibility and 2 more. Started Jul 2024; status: completed.
02
Drugs
empagliflozinfinerenone
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on NL-OMON59957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59957.